Ann: Quarterly Report and Appendix 4C - quarterly, page-5

Accumulated a couple of parcels(av 74c) and plenty of upcoming newsflow as well as tax rebate and option conversion ensuring adequately funding.
This is rare for a pharma company -

Clinical Development Progress

Phase 2b - Osteoarthritis / Bone Marrow Lesions Paradigm is progressing ahead of schedule with the phase 2b, randomised double-blind placebo-controlled multicentre clinical trial to evaluate the effects of injectable pentosan polysulfate sodium (iPPS) on pain in participants with knee osteoarthritis and concurrent subchondral bone marrow lesions (n=110).

Recruitment Status • Trial is ahead of schedule, with final recruitment imminent • Interest in the clinical trial has been exceedingly high from people with osteoarthritis

Paradigm is very pleased with the management of the clinical trial and the strong momentum it has been able to maintain. The phase 2b clinical trial remains ahead of schedule with the pivotal results expected in Q4 CY2018.